Disclosures for "Phase 3 EPIC (EPIlepsy Cell Therapy) Clinical Trial Design: NRTX-1001 GABAergic Interneuron Cell Therapy for the Treatment of Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)"